Client

Precision Oncology Biotechnology Company, North America

Programme

Antibody-Drug Conjugate (ADC) Development

Stage

Preclinical to Clinical Manufacturing Readiness

Challenge

The client was advancing a novel ADC programme and required a comprehensive manufacturing and development strategy spanning multiple specialised activities.

Unlike conventional biologics, ADC development introduced additional complexities involving potent payload handling, linker technologies, conjugation processes, analytical characterisation, and containment requirements.

No single organisation possessed best-in-class capabilities across all required activities, necessitating the identification and coordination of multiple specialised partners.

Aventiq Bio Approach

Aventiq Bio developed an integrated outsourcing strategy designed to support efficient programme progression while minimising technical and execution risks.

The team evaluated potential manufacturing partners across the entire ADC value chain and established a coordinated development framework aligned with the client's timelines and objectives

Key Activities

• Assessed monoclonal antibody manufacturing capabilities
• Evaluated linker and payload development expertise
• Reviewed conjugation process development platforms
• Analysed containment capabilities for highly potent compounds
• Evaluated analytical characterisation and quality control infrastructure
• Assessed technology transfer experience and regulatory support capabilities
• Reviewed capacity availability, scheduling constraints, and programme fit
• Established governance frameworks for cross-vendor collaboration
• Supported technical discussions and strategic decision-making

Outcome

Aventiq Bio enabled the client to establish a fit-for-purpose CDMO ecosystem capable of supporting ADC development from process development through future clinical manufacturing activities.

The integrated approach improved programme visibility, reduced vendor selection risk, and strengthened collaboration across multiple specialised partners.

Client Perspective

Developing an ADC required coordination across specialised manufacturing and analytical partners. Aventiq Bio helped us evaluate CDMO capabilities, identify key risks, and establish a manufacturing strategy that balanced technical excellence, scalability, and programme timelines. Their oversight brought clarity to a highly complex outsourcing landscape

— Vice President, CMC, Oncology Biotechnology Company, North America